Last $6.10 USD
Change Today +0.22 / 3.74%
Volume 63.4K
QLTI On Other Exchanges
As of 4:30 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

qlt inc (QLTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $7.10
52 Week Low
09/4/13 - $4.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QLT INC (QLTI)

qlt inc (QLTI) Related Businessweek News

No Related Businessweek News Found

qlt inc (QLTI) Details

QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.

37 Employees
Last Reported Date: 02/28/14
Founded in 1981

qlt inc (QLTI) Top Compensated Officers

Principal Executive Officer, Independent Dire...
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $233.8K
Compensation as of Fiscal Year 2013.

qlt inc (QLTI) Key Developments

QLT Inc. Announces Publication in the Lancet of Phase 1B Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations

QLT Inc. announced the publication of data from its Phase 1b proof-of-concept trial of QLT091001 in subjects with Leber Congenital Amaurosis (LCA) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT) in The Lancet. In the study, treatment for 7 days with oral QLT091001 demonstrated a restoration of clinically meaningful visual function in 11 of the 14 LCA patients, as measured by improvement in Goldmann Visual Fields (GVF) or visual acuity. Self-reported or parent-reported improvements in activities of daily living supported these findings. The trial enrolled 14 patients, ages 6--38, with Leber Congenital Amaurosis due to mutations in RPE65 or LRAT. Patients received 7 days of oral QLT091001 (12 subjects received 40 mg/m(2) per day and 2 subjects received 10 mg/m(2) per day). Patients were assessed at baseline and days 7, 9, 14, and 30, and every 2 months thereafter, for up to 3 years, for safety outcomes and visual function endpoints, which included GVF, visual acuity, and a functional MRI assessment. In the study, 10 of 14 patients had an improvement of GVF, with a mean increase in retinal area of 28--683%. Six patients had an improvement in visual acuity, with a mean increase of 2--30 letters. After two years, three patients had a sustained GVF response and four had a sustained visual acuity response. Four patients had functional MRI scans, which correlated with visual response or absence of response to treatment. Ten of the responders had self-reported improvements in activities of daily living. No serious adverse events occurred, although transient headaches, photophobia, reduction in serum HDL concentrations, and mild, reversible increases in serum triglycerides and aspartate aminotransferase concentrations were observed.

Auxilium Pharmaceuticals Inc., QLT Inc. - M&A Call

To discuss agreement and plan of merger among QLT, Auxilium Pharmaceuticals, Inc

QLT Inc. Announces Resignation of Alexander R. Lussow, Senior Vice President, Business Development and Commercial Operations

QLT Inc. entered into a letter agreement with Alexander R. Lussow, the company’s Senior Vice President, Business Development and Commercial Operations, in which the company, among other things, agreed that it would terminate Mr. Lussow on either, in the company’s discretion, March 31, 2014, April 30, 2014 or May 31, 2014. Mr. Lussow was terminated effective May 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLTI:US $6.10 USD +0.22

QLTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLTI.
View Industry Companies

Industry Analysis


Industry Average

Valuation QLTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at